FOLH1 and neoplasm: [177Lu]Lu-HTK03149 delivers 145% higher absorbed dose to LNCaP tumor xenografts than [177Lu]Lu-PSMA-617 because of its higher peak tumor uptake (20.9±2.99 %IA/g) and sustained tumor retention.